

# Hypothyroidism Pharmaceutical and Healthcare Pipeline Review H2

*Hypothyroidism Therapeutic Pipeline Market Review, H2 2016*

PUNE, INDIA, January 6, 2017  
/EINPresswire.com/ -- Get Sample Report @  
<https://www.wiseguyreports.com/sample-request/794444-hypothyroidism-pipeline-review-h2-2016>

Hypothyroidism - Pipeline Review, H2 2016

Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.



**WISE GUY**  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

## Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 5 respectively.Hypothyroidism.

Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

## Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism

(Hormonal Disorders).

- The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Buy now @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=794444](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=794444)

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Hypothyroidism Overview 6

Therapeutics Development 7

Pipeline Products for Hypothyroidism - Overview 7

Hypothyroidism - Therapeutics under Development by Companies 8

Hypothyroidism - Pipeline Products Glance 9

Late Stage Products 9

Early Stage Products 10

Hypothyroidism - Products under Development by Companies 11

Hypothyroidism - Companies Involved in Therapeutics Development 12

Synthonics Inc 12

Titan Pharmaceuticals Inc 13  
Hypothyroidism - Therapeutics Assessment 14  
Assessment by Monotherapy Products 14  
Assessment by Combination Products 15  
Assessment by Target 16  
Assessment by Mechanism of Action 17  
Assessment by Route of Administration 18  
Assessment by Molecule Type 20  
Drug Profiles 21  
(levothyroxine + liothyronine) - Drug Profile 21  
Product Description 21  
Mechanism Of Action 21  
R&D Progress 21  
BCT-305 - Drug Profile 22  
Product Description 22  
Mechanism Of Action 22  
R&D Progress 22  
levothyroxine sodium SR - Drug Profile 23  
Product Description 23  
...Continued

Access Report @ <https://www.wiseguyreports.com/reports/794444-hypothyroidism-pipeline-review-h2-2016>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.